Public preview. Funding rounds, founders, and growth signals require a free account.

Acer Therapeutics Inc.

Acer Therapeutics develops therapies for patients with serious, rare, and life-threatening diseases, with a focus on conditions such as maple syrup urine disease and vascular Ehlers-Danlos syndrome. The company's pipeline includes OLPRUVA and EDSIVO, therapeutic candidates targeting these rare genetic disorders.

Series BPharmaCambridge, MA1-10 employees

Total raised

$37.2M

Last round

Equity

$15.7M · Sep 2017

Stage

Series B

Status

Active

Founders & team

Co-founder, CEO

Co-founder, CTO

Head of Engineering

Head of Sales

🔒

Sign up to see founders

Free account unlocks founder names, LinkedIn profiles, and prior companies.

Create free account

Growth signals

Web traffic

Search interest

Social followers

Glassdoor rating

News mentions

Gov contracts

🔒

Sign up to see signals

Free account unlocks 5 full profiles per day. Pro removes the limit.

Create free account

Track Acer Therapeutics Inc. on FlareSight

Get notified the moment Acer Therapeutics Inc. files a new round, hires execs, or shows traction signals.

Create free account

About this data

FlareSight surfaces funding data from SEC Form D filings within hours of submission. Browse our full startup funding database to find more recently funded companies.